• LAST PRICE
    5.5100
  • TODAY'S CHANGE (%)
    Trending Down-0.0900 (-1.6071%)
  • Bid / Lots
    5.4700/ 2
  • Ask / Lots
    5.5600/ 1
  • Open / Previous Close
    5.5100 / 5.6000
  • Day Range
    Low 5.5100
    High 5.5100
  • 52 Week Range
    Low 2.3600
    High 9.6100
  • Volume
    1,624

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 5.6
TimeVolumeORIC
09:32 ET16135.51
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesORIC
Oric Pharmaceuticals Inc
251.7M
-2.4x
---
United StatesRLYB
Rallybio Corp
252.6M
-3.2x
---
United StatesNAUT
Nautilus Biotechnology Inc
254.4M
-4.1x
---
United StatesLRMR
Larimar Therapeutics Inc
254.4M
-3.3x
---
United StatesPDSB
PDS Biotechnology Corp
246.1M
-8.4x
---
United StatesGOSS
Gossamer Bio Inc
257.9M
-1.0x
---
As of 2023-02-08

Company Information

ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in improving patients' lives by Overcoming Resistance In Cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its clinical-stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. ORIC-114, is a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency towards exon 20 insertion mutations. ORIC-944 is an allosteric inhibitor of the polycomb repressive complex 2 (PRC2).

Contact Information

Headquarters
240 E. Grand Ave., 2nd FloorSOUTH SAN FRANCISCO, CA, United States 94080
Phone
650-388-5600
Fax
302-655-5049

Executives

Independent Chairman of the Board
Richard Heyman
President, Chief Executive Officer, Director
Jacob Chacko
Chief Financial Officer
Dominic Piscitelli
Chief Medical Officer
Pratik Multani
Independent Director
Mardi Dier

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$251.7M
Revenue (TTM)
$0.00
Shares Outstanding
45.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.31
Book Value
$6.92
P/E Ratio
-2.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.